Totient, a Viva Biotech portfolio company, has been acquired by AbSci, a synthetic biology company working with proteins as next-generation therapeutics. Totient is a biotech company, harnessing human immune responses to identify novel antibodies and their therapeutic targets. This acquisition adds antibody and target discovery technology to AbSci’s platform for therapeutic protein design and biomanufacturing optimization.   The development of predictive models that encompass the interacti...